295 related articles for article (PubMed ID: 20720209)
1. Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice.
Reboulet RA; Hennies CM; Garcia Z; Nierkens S; Janssen EM
J Immunol; 2010 Sep; 185(6):3337-47. PubMed ID: 20720209
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes.
Katz JD; Ondr JK; Opoka RJ; Garcia Z; Janssen EM
J Immunol; 2010 Aug; 185(4):1999-2003. PubMed ID: 20644171
[TBL] [Abstract][Full Text] [Related]
4. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
5. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
[TBL] [Abstract][Full Text] [Related]
6. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
7. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
8. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
9. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
Milling SW; Sai T; Silvers WK; Mintz B
Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
[TBL] [Abstract][Full Text] [Related]
11. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
[TBL] [Abstract][Full Text] [Related]
12. Twist1 promotes dendritic cell-mediated antitumor immunity.
Luo Y; Chen J; Liu M; Chen S; Su X; Su J; Zhao C; Han Z; Shi M; Ma X; Huang H
Exp Cell Res; 2020 Jul; 392(2):112003. PubMed ID: 32278689
[TBL] [Abstract][Full Text] [Related]
13. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
14. Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.
Lorenzi S; Mattei F; Sistigu A; Bracci L; Spadaro F; Sanchez M; Spada M; Belardelli F; Gabriele L; Schiavoni G
J Immunol; 2011 May; 186(9):5142-50. PubMed ID: 21441457
[TBL] [Abstract][Full Text] [Related]
15. β-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8⁺ T cells.
Liang X; Fu C; Cui W; Ober-Blöbaum JL; Zahner SP; Shrikant PA; Clausen BE; Flavell RA; Mellman I; Jiang A
J Leukoc Biol; 2014 Jan; 95(1):179-90. PubMed ID: 24023259
[TBL] [Abstract][Full Text] [Related]
16. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
17. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
18. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
[TBL] [Abstract][Full Text] [Related]
19. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.
Tel J; Schreibelt G; Sittig SP; Mathan TS; Buschow SI; Cruz LJ; Lambeck AJ; Figdor CG; de Vries IJ
Blood; 2013 Jan; 121(3):459-67. PubMed ID: 23212525
[TBL] [Abstract][Full Text] [Related]
20. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]